Active, not recruitingInterventional · Phase 2NCT03375307 ↗A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Active, not recruitingInterventional · Phase 3NCT03682068 ↗A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.Scott T. TagawaPIInterventionDrug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin + Gemcitabine · Drug: Carboplatin + GemcitabineDatesSep 2018 – Jun 2026SponsorAstraZeneca Pharmaceuticals LPUnresectable Locally Advanced Urothelial CancerMetastatic Urothelial Cancer
RecruitingInterventional · Phase 2NCT03866382 ↗A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)Cora SternbergPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib S-malate · Procedure: Computed Tomography · Procedure: Echocardiography Test · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission TomographyDatesMay 2019 – Feb 2027 (est.)SponsorAlliance for Clinical Trials in OncologyBladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more
Active, not recruitingInterventional · Phase 2NCT04164082 ↗Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder CancerCora SternbergPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Cystoscopy · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Biological: Pembrolizumab · Procedure: Transurethral Resection of Bladder TumorDatesMar 2020 – Dec 2026 (est.)SponsorAlliance for Clinical Trials in OncologyBladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
Active, not recruitingInterventional · Phase 1NCT04794699 ↗An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid TumorsBarbara MaPIInterventionDrug: IDE397 · Drug: Sacituzumab govitecanDatesApr 2021 – Jan 2027 (est.)SponsorIDEAYA BiosciencesSolid Tumor
Active, not recruitingInterventional · Phase 1NCT04963153 ↗Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic AlterationsRohit Kumar JainPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Scan · Procedure: Computed Tomography · Procedure: Echocardiography Test · Drug: Enfortumab Vedotin · Drug: Erdafitinib · Procedure: Multigated Acquisition ScanDatesJul 2022 – Dec 2026 (est.)SponsorNational Cancer InstituteLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+17 more
RecruitingInterventional · Phase 1NCT05614739 ↗FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 AlterationsRohit Kumar JainPIInterventionDrug: Vepugratinib · Drug: Pembrolizumab · Drug: enfortumab vedotin · Drug: Trastuzumab Deruxtecan · Drug: Midazolam · Drug: Digoxin · Drug: RosuvastatinDatesJan 2023 – Jun 2027 (est.)SponsorEli Lilly and CompanyUrinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
RecruitingInterventional · Phase 2NCT07061964 ↗Single Arm Phase II Study of Bladder Preservation With Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (BRIGHT)Rohit Kumar JainPIInterventionProcedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Cystoscopy · Procedure: Magnetic Resonance Imaging · Biological: Pembrolizumab · Radiation: Photon Beam Radiation Therapy · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Procedure: Transurethral Resection of Bladder TumorDatesNov 2025 – Jul 2027 (est.)SponsorSWOG Cancer Research NetworkMuscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
CompletedInterventional · Phase 2NCT03558503 ↗A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of RecurrenceDouglas S ScherrPIInterventionDrug: UGN-102DatesOct 2018 – Jan 2020· Results postedSponsorUroGen Pharma Ltd.Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
CompletedInterventional · Phase 1/2NCT04045613 ↗An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR AberrationsCora SternbergPIInterventionDrug: Derazantinib 300 mg once daily monotherapy · Drug: Derazantinib 200 mg once daily + atezolizumab 1200 mg · Drug: Derazantinib 300 mg once daily+ atezolizumab 1200 mg · Drug: Derazantinib 200 mg twice daily + atezolizumab 1200 mg · Drug: Derazantinib 300 mg once daily monotherapy (QD) · Drug: Derazantinib 300 mg once daily + atezolizumab 1200 mg · Drug: Derazantinib 200 mg twice daily monotherapyDatesAug 2019 – Oct 2022· Results postedSponsorBasilea Pharmaceutica, Ltd.Urothelial Carcinoma
TerminatedInterventional · Phase 1NCT04254107 ↗A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced MalignanciesAnna C PavlickPIInterventionDrug: SEA-TGT · Drug: sasanlimab · Drug: brentuximab vedotinDatesMay 2020 – Dec 2023SponsorSeagen Inc.Non-small Cell Lung CancerGastric CarcinomaGastroesophageal Junction Carcinoma+9 more
TerminatedInterventional · Phase 2NCT04936230 ↗Phase II Randomized Trial of Immunotherapy Versus Immunotherapy and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (IMMORTAL)Scott T. TagawaPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Scan · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Biological: Pembrolizumab · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Radiation: Stereotactic Body Radiation TherapyDatesNov 2022 – Aug 2024· Results postedSponsorAlliance for Clinical Trials in OncologyMetastatic Urothelial CarcinomaPlatinum-Resistant Urothelial CarcinomaStage IV Bladder Cancer AJCC v8